Created at	Source	Raw Value	Validated value
May 3, 2022, 4 p.m.	eu	1. Percentage of participants who have undetectable SARS-CoV-2 in baseline NP swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 2. Percentage of participants with ≥1 adverse event 3. Percentage of participants discontinuing from study therapy due to AE	1. Percentage of participants who have undetectable SARS-CoV-2 in baseline NP swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 2. Percentage of participants with ≥1 adverse event 3. Percentage of participants discontinuing from study therapy due to AE